We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
- Authors
Watanabe, Hiroki; Ozasa, Neiko; Morimoto, Takeshi; Shiomi, Hiroki; Bingyuan, Bao; Suwa, Satoru; Nakagawa, Yoshihisa; Izumi, Chisato; Kadota, Kazushige; Ikeguchi, Shigeru; Hibi, Kiyoshi; Furukawa, Yutaka; Kaji, Shuichiro; Suzuki, Takahiko; Akao, Masaharu; Inada, Tsukasa; Hayashi, Yasuhiko; Nanasato, Mamoru; Okutsu, Masaaki; Kametani, Ryosuke
- Abstract
Background: Despite its recommendation by the current guidelines, the role of long-term oral beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST-segment elevation myocardial infarction (STEMI) patients without heart failure, left ventricular dysfunction or ventricular arrhythmia who underwent primary percutaneous coronary intervention (PCI). Methods and results: In a multi-center, open-label, randomized controlled trial, STEMI patients with successful primary PCI within 24 hours from the onset and with left ventricular ejection fraction (LVEF) ≥40% were randomly assigned in a 1-to-1 fashion either to the carvedilol group or to the no beta-blocker group within 7 days after primary PCI. The primary endpoint is a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome. Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. The carvedilol dose was up-titrated from 3.4±2.1 mg at baseline to 6.3±4.3 mg at 1-year. During median follow-up of 3.9 years with 96.4% follow-up, the cumulative 3-year incidences of both the primary endpoint and any coronary revascularization were not significantly different between the carvedilol and no beta-blocker groups (6.8% and 7.9%, P = 0.20, and 20.3% and 17.7%, P = 0.65, respectively). There also was no significant difference in LVEF at 1-year between the 2 groups (60.9±8.4% and 59.6±8.8%, P = 0.06) Conclusion: Long-term carvedilol therapy added on the contemporary evidence-based medications did not seem beneficial in selected STEMI patients treated with primary PCI. Trial registration: CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-scale Randomized Controlled Trial) ClinicalTrials.gov.number, .
- Subjects
CARVEDILOL; MYOCARDIAL infarction; PERCUTANEOUS coronary intervention; REVASCULARIZATION (Surgery); VENTRICULAR arrhythmia
- Publication
PLoS ONE, 2018, Vol 13, Issue 8, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0199347